Skip to main content

Myositis

ILD studied in 679 inflammatory idiopathic myositis (IIM) pts; 508 had ILD (found in 93% amyopathic DM, 74% DM & 55% PM). Prevalence of of ILD was higher with antisynthetase Ab + and MDA-5 Ab +.

Dr. John Cush RheumNow ( View Tweet)

Sep 14, 2020

RheumNow Podcast – Rheum Lives Matter (8.28.20)

Aug 28, 2020

Dr. Jack Cush reviews the news and journal articles from the past week. Of mice and men in cartilage, the efficacy of JAK inhibitors in patients who are having skin problems, nrAxSpa has its own diagnostic code, metformin, talking about Back Talk, plus so much more.

Read Article
Hong Kong study Myositis-specific autoantibodies in 201 pts with idiopathic inflammatory myopathies (IIM) shows MDA-5 (14%), TIFF-1γ (14%), Jo-(12.4%). MDA5 seen w/ DM, digital ulcers, amyopathy, ILD.

Dr. John Cush RheumNow ( View Tweet)

Aug 07, 2020

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article
Fracture risk & prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional comparison of 52 myositis and 43 RA pts.

Dr. John Cush RheumNow ( View Tweet)

Jul 31, 2020

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jul 24, 2020

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jul 17, 2020

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article
Retrospective study of 603 myositis (IIM), 4047 RA and 4061 controls shows IIM has higher risk of CV events (HR 1.38) and MI [HR 1.61] but not CVA [HR 0.92]. The CV risk in IIM was equal to that in RA [HR 1.01].

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2020
Systematic review of DYSPHAGIA in inflammatory myositis finds it may be an initial or sole symptom. Prevalence in IIM was 36% and higher 56% inclusion body myositis, cancer or NXP2 -associated myositis.

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2020

CV Risks Raised in Myopathies

Jul 02, 2020

Patients with the idiopathic inflammatory myopathies (IIMs) dermatomyositis and polymyositis are at increased risk for cardiovascular events, with risks similar to what has been documented for rheumatoid arthritis (RA), during the first 5 years after diagnosis, U.K. researchers reported.

Read Article
#EULAR2020 #op0169 US claims database analysis reveals that gout and DM make for a dangerous combination: significantly higher risk of amputations in pts with gout+DM at 0.77% as oppose to DM w/out gout 0.461% & gout w/out DM 0.162% @RheumNow

Olga Petryna DrPetryna ( View Tweet)

Jun 07, 2020
#EULAR2020 Recc for irAEs w/ICI: 1. GC's ok, goal<10 mg/d, any csDMARD, bDMARD (TNFi/IL-6),🚫ABT xcept life-threatening myositis 2. Myositis beware bulbar signs: dysphagia, dysarthria, dysphonia: stop ICIs,⬆️GC, IVIG/PE 3.
Jun 06, 2020

Lenabasum Encouraging in Systemic Sclerosis

Apr 30, 2020

The oral cannabinoid receptor type 2 (CB2) agonist lenabasum showed promising results for systemic sclerosis (SSc) in a phase II study.

At week 16, the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) increased to 0.33 among

Read Article

RheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)

Jan 31, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

Treatment of Statin-induced anti-HMGCR myopathy

Jan 10, 2020

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of

Read Article

ACR 2018 - Day 3 Report

Jan 09, 2020

Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included the PEXIVAS Study, ACR Reproductive Health Draft Guidelines, and a Proof of concept study

Read Article

RheumNow Podcast – Women Take Over Rheumatology (10.4.19)

Oct 04, 2019

Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.

Read Article

Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors

Sep 23, 2019

Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.

Read Article

Checkpoint Inhibitors: Who Gets Myocarditis?

Aug 28, 2019

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

Myocarditis associated with immune checkpoint inhibitors (ICIs) was nearly twice as likely in women (OR 1.92, 95% CI 1.24-2.97

Read Article

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Aug 23, 2019

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.

Read Article

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Aug 02, 2019

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com:
MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.

Read Article

RheumNow Podcast – Don’t Take My Advice (7.19.19)

Jul 19, 2019

Dr. Jack Cush reports the news and new journal articles from the past week on RheumNow.com.

Read Article

Predictors of Serious Infections with Rituximab

May 28, 2019

The risk of serious infectious events (SIE) with rituximab (RTX) is similar to that seen in other biologics (e.g., RA: 2% or 4.3/100PY), but with prolonged use the risk may change. Recent research says that low IgG levels, RTX induced neutropenia, prior SIE and comorbidities can significantly

Read Article

RheumNow Podcast – Richer or Poorer (5.17.19)

May 17, 2019

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
×